Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–33.
CAS
PubMed
Article
Google Scholar
van Gijn W, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575–82.
PubMed
Article
Google Scholar
Juul T, et al. Low anterior resection syndrome and quality of life: an international multicenter study. Dis Colon rectum. 2014;57(5):585–91.
PubMed
Article
Google Scholar
Lange MM, et al. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg. 2008;95(8):1020–8.
CAS
PubMed
Article
Google Scholar
Hendren SK, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg. 2005;242(2):212–23.
PubMed
PubMed Central
Article
Google Scholar
Alves A, et al. Mortality and morbidity after surgery of mid and low rectal cancer. Results of a French prospective multicentric study. Gastroenterol Clin Biol. 2005;29(5):509–14.
PubMed
Article
Google Scholar
Paun BC, et al. Postoperative complications following surgery for rectal cancer. Ann Surg. 2010;251(5):807–18.
Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon rectum. 1974;17(3):354–6.
CAS
PubMed
Article
Google Scholar
Hartley A, et al. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol. 2005;78(934):934–8.
CAS
PubMed
Article
Google Scholar
Habr-Gama A, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7. discussion 717-8
PubMed
PubMed Central
Google Scholar
Rasheed S, et al. Can depth of tumour invasion predict lymph node positivity in patients undergoing resection for early rectal cancer? A comparative study between T1 and T2 cancers. Color Dis. 2008;10(3):231–8.
CAS
Article
Google Scholar
• Habr-Gama A et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy dose-escalation and consolidation chemotherapy. Ann Surg. 2017. The latest report on watch-and-wait from the group that pioneered this approach.
Lezoche E, et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg. 2012;99(9):1211–8.
CAS
PubMed
Article
Google Scholar
• Garcia-Aguilar J, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015;16(15):1537–46. One of the few prospective studies on organ preservation in early stage rectal cancer.
PubMed
PubMed Central
Article
Google Scholar
Noh JM, et al. Outcome of local excision following preoperative chemoradiotherapy for clinically T2 distal rectal cancer: a multicenter retrospective study (KROG 12-06). Cancer Res Treat. 2014;46(3):243–9.
CAS
PubMed
PubMed Central
Article
Google Scholar
Bonnen M, et al. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys. 2004;60(4):1098–105.
PubMed
Article
Google Scholar
Balyasnikova S, et al. The results of local excision with or without postoperative adjuvant chemoradiotherapy for early rectal cancer among patients choosing to avoid radical surgery. Color Dis. 2017;19(2):139–47.
CAS
Article
Google Scholar
Adam IJ, et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet. 1994;344(8924):707–11.
CAS
PubMed
Article
Google Scholar
Taylor FG, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol. 2014;32(1):34–43.
PubMed
Article
Google Scholar
Nagtegaal ID, et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol. 2005;23(36):9257–64.
PubMed
Article
Google Scholar
Marr R, et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg. 2005;242(1):74–82.
PubMed
PubMed Central
Article
Google Scholar
Group, M.S. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333(7572):779.
Article
Google Scholar
•• Battersby NJ, et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II Study. Ann Surg. 2016;263(4):751–60. A key study that validated the use of MRI in rectal staging and surgical plane assessment in low rectal cancer.
PubMed
Article
Google Scholar
Pucciarelli S, et al. Bowel function and quality of life after local excision or total mesorectal excision following chemoradiotherapy for rectal cancer. Br J Surg. 2017;104(1):138–47.
CAS
PubMed
Article
Google Scholar
Emmertsen KJ, Laurberg S. Bowel dysfunction after treatment for rectal cancer. Acta Oncol. 2008;47(6):994–1003.
PubMed
Article
Google Scholar
Bryant CLC, et al. Anterior resection syndrome. Lancet Oncol. 2012;13(9):e403–8.
PubMed
Article
Google Scholar
Bregendahl S, et al. Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: a population-based cross-sectional study. Color Dis. 2013;15(9):1130–9.
CAS
Google Scholar
Schiller DE, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007;14(10):2780–9.
PubMed
Article
Google Scholar
Papaconstantinou HT, et al. Salvage abdominoperineal resection after failed Nigro protocol: modest success, major morbidity. Color Dis. 2006;8(2):124–9.
CAS
Article
Google Scholar
Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.
CAS
PubMed
Article
Google Scholar
Ngan SY, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827–33.
PubMed
Article
Google Scholar
Bujko K, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–23.
CAS
PubMed
Article
Google Scholar
De Caluwe L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev. 2013;2:CD006041.
Google Scholar
Bujko K et al. The feasibility of short-course radiotherapy in a watch-and-wait policy for rectal cancer. Acta Oncol. 2017;1–3. https://doi.org/10.1080/0284186X.2017.1327721
Erlandsson J, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18(3):336–46.
PubMed
Article
Google Scholar
Pettersson D, et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg. 2015;102(8):972–8. discussion 978
CAS
PubMed
PubMed Central
Article
Google Scholar
Frin AC, et al. Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients. Eur J Cancer. 2017;72:124–36.
PubMed
Article
Google Scholar
Gerard JP, et al. French experience with contact X-ray endocavitary radiation for early rectal cancer. Clin Oncol (R Coll Radiol). 2007;19(9):661–73.
CAS
Article
Google Scholar
Sun Myint A, et al. Dose escalation using contact x-ray brachytherapy (Papillon) for rectal cancer. Does it improve the chance of organ preservation? Br J Radiol. 2017;90(1080):20170175.
PubMed
Article
Google Scholar
Dhadda AS, et al. Organ preservation using contact radiotherapy for early rectal cancer: outcomes of patients treated at a single centre in the UK. Clin Oncol (R Coll Radiol). 2017;29(3):198–204.
CAS
Article
Google Scholar
Gerard JP, et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the Lyon R96-02 randomized trial. J Clin Oncol. 2004;22(12):2404–9.
PubMed
Article
Google Scholar
•• Rodel C, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89. An important study on the addition of oxaliplatin in rectal cancer.
PubMed
Article
CAS
Google Scholar
Aschele C, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773–80.
CAS
PubMed
Article
Google Scholar
Gerard JP, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638–44.
CAS
PubMed
Article
Google Scholar
Allegra CJ, et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015;107(11). https://doi.org/10.1093/jnci/djv248
Schmoll HJ, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: final analyses. Ann Oncol. 2016;27(suppl_6). https://doi.org/10.1093/annonc/mdw370.16
• Deng Y, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. J Clin Oncol. 2016;34(27):3300–7. Another important study on the addition of oxaliplatin in rectal cancer.
CAS
PubMed
Article
Google Scholar
Yang YJ, et al. Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: an updated systematic review and meta-analysis. Oncotarget. 2016;7(29):45513–24.
PubMed
PubMed Central
Article
Google Scholar
Smith JJ, et al. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767.
PubMed
PubMed Central
Article
CAS
Google Scholar
Schrag D, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32(6):513–8.
CAS
PubMed
PubMed Central
Article
Google Scholar
Fernandez-Martos C, et al. Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial. Oncologist. 2014;19(10):1042–3.
PubMed
PubMed Central
Article
Google Scholar
Patel UB, et al. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial. Ann Oncol. 2017;28(2):344–53.
CAS
PubMed
Article
Google Scholar
Appelt AL, et al. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(1):74–80.
PubMed
Article
Google Scholar
Buckley H, Wilson C, Ajithkumar T. High-dose-rate brachytherapy in the management of operable rectal cancer: a systematic review. Int J Radiat Oncol Biol Phys. 2017;99(1):111–27.
PubMed
Article
Google Scholar
• Appelt AL, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16(8):919–27. A prospective study on organ preservation in rectal cancer.
PubMed
Article
Google Scholar
Vuong T, Devic S, Podgorsak E. High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer. Clin Oncol (R Coll Radiol). 2007;19(9):701–5.
CAS
Article
Google Scholar
Vuong T, Devic S. High-dose-rate pre-operative endorectal brachytherapy for patients with rectal cancer. J Contemp Brachytherapy. 2015;7(2):183–8.
PubMed
PubMed Central
Article
Google Scholar
Dalton RS, et al. A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management? Color Dis. 2012;14(5):567–71.
CAS
Article
Google Scholar
Creavin B, et al. Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer. Br J Cancer. 2017;116(2):169–74.
CAS
PubMed
Article
Google Scholar
Martens MH, et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst. 2016;108(12). https://doi.org/10.1093/jnci/djw171
Nahas SC, et al. Pathologic complete response in rectal cancer: can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer. Dis Colon rectum. 2016;59(4):255–63.
PubMed
Article
Google Scholar
Habr-Gama A, et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon rectum. 2009;52(12):1927–34.
PubMed
Article
Google Scholar
Lai CL, et al. Rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or “watch and wait”. Int J Color Dis. 2016;31(2):413–9.
Article
Google Scholar
Vaccaro CA, et al. Locally advanced rectal cancer: preliminary results of rectal preservation after neoadjuvant chemoradiotherapy. Cir Esp. 2016;94(5):274–9.
PubMed
Article
Google Scholar
Renehan AG, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17(2):174–83.
PubMed
Article
Google Scholar
Smith JD, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256(6):965–72.
PubMed
Article
Google Scholar
Wolthuis AM, et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol. 2012;19(9):2833–41.
PubMed
Article
Google Scholar
Sloothaak DA, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2013;100(7):933–9.
CAS
PubMed
Article
Google Scholar
Tulchinsky H, et al. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008;15(10):2661–7.
PubMed
Article
Google Scholar
Garcia-Aguilar J, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254(1):97–102.
PubMed
PubMed Central
Article
Google Scholar
Garcia-Aguilar J, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957–66.
CAS
PubMed
PubMed Central
Article
Google Scholar
•• Lefevre JH, et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: A multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. 2016;34(31):3773–80. https://doi.org/10.1200/JCO.2016.67.6049. A significant study on timing of surgery following neoadjuvant chemoradiation.
PubMed
Article
Google Scholar
Habr-Gama A, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys. 2008;71(4):1181–8.
PubMed
Article
Google Scholar
Kerr SF, Norton S, Glynne-Jones R. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. Br J Surg. 2008;95(12):1534–40.
CAS
PubMed
Article
Google Scholar
•• Evans J, et al. Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy? ESMO annual meeting 2016, Abstract 452O. An important study on timing of surgery.
Sun Z, et al. Optimal timing to surgery after neoadjuvant chemoradiotherapy for locally advanced rectal cancer. J Am Coll Surg. 2016;222(4):367–74.
PubMed
Article
Google Scholar
Probst CP, et al. Extended intervals after neoadjuvant therapy in locally advanced rectal cancer: the key to improved tumor response and potential organ preservation. J Am Coll Surg. 2015;221(2):430–40.
PubMed
PubMed Central
Article
Google Scholar
• Petrelli F, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016;263(3):458–64. A meta-analysis on timing of surgery following neoadjuvant chemoradiation.
PubMed
Article
Google Scholar
Maas M, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–40.
PubMed
Article
Google Scholar
Perez RO, et al. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer? Color Dis. 2012;14(6):714–20.
CAS
Article
Google Scholar
Verseveld M, et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg. 2015;102(7):853–60.
CAS
PubMed
Article
Google Scholar
• Habr-Gama A, et al. Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation. Dis Colon Rectum. 2016;59(4):264–9. One of the few studies on function and quality of life with organ preservation strategies in rectal cancer.
PubMed
Article
Google Scholar
Habr-Gama A, et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon rectum. 2010;53(12):1692–8.
PubMed
Article
Google Scholar
Perez RO, et al. Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: long-term results of a prospective trial (National Clinical Trial 00254683). Cancer. 2012;118(14):3501–11.
PubMed
Article
Google Scholar
Patel UB, et al. MRI after treatment of locally advanced rectal cancer: how to report tumor response—the MERCURY experience. AJR Am J Roentgenol. 2012;199(4):W486–95.
PubMed
Article
Google Scholar
Patel UB, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011;29(28):3753–60.
PubMed
Article
Google Scholar
Siddiqui MR, et al. Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG). Clin Radiol. 2016;71(9):854–62.
CAS
PubMed
Article
Google Scholar
Bhoday J, et al. Magnetic resonance tumor regression grade and residual mucosal abnormality as predictors for pathological complete response in rectal cancer postneoadjuvant chemoradiotherapy. Dis Colon rectum. 2016;59(10):925–33.
PubMed
Article
Google Scholar
Maas M, et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: Selection for organ-saving treatment. Ann Surg Oncol. 2015;22(12):3873–80.
PubMed
PubMed Central
Article
Google Scholar
Battersby NJ, Balyasnikova S, Brown G. Guiding post-treatment decisions in rectal cancer: mrTRG is a practical place to start. Oncology (Williston Park). 2014;28(8):677–80.
Google Scholar
Kim SH, et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology. 2009;253(1):116–25.
PubMed
Article
Google Scholar
Sun YS, et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology. 2010;254(1):170–8.
PubMed
Article
Google Scholar
• Ryan JE, et al. Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2015;17(10):849–61. A good review on methods to assess response to treatment.
CAS
PubMed
Article
Google Scholar
•• Battersby NJ, et al. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials. 2017;18(1):394. A description of the TRIGGER trial, an ongoing prospective study including watch-and-wait as a therapeutic strategy.
PubMed
PubMed Central
Article
Google Scholar
Sun Y, et al. A nomogram predicting pathological complete response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer: implications for organ preservation strategies. Oncotarget. 2017;8(40):67732–43.
PubMed
PubMed Central
Google Scholar
Zhang J, et al. Nomogram basing pre-treatment parameters predicting early response for locally advanced rectal cancer with neoadjuvant chemotherapy alone: a subgroup efficacy analysis of FOWARC study. Oncotarget. 2016;7(4):5053–62.
PubMed
Google Scholar
van Stiphout RG, et al. Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET-CT imaging. Radiother Oncol. 2011;98(1):126–33.
PubMed
Article
Google Scholar
McCawley N, et al. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Dis Colon rectum. 2016;59(12):1200–8.
PubMed
Article
Google Scholar
Bettoni F, et al. Intratumoral genetic heterogeneity in rectal cancer: are single biopsies representative of the entirety of the tumor? Ann Surg. 2017;265(1):e4–6.
PubMed
Article
Google Scholar
Park YA, et al. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol. 2006;93(2):145–50.
PubMed
Article
Google Scholar
Yoon SM, et al. Clinical parameters predicting pathologic tumor response after preoperative chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2007;69(4):1167–72.
PubMed
Article
Google Scholar
Perez RO, et al. The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis Colon Rectum. 2009;52(6):1137–43.
PubMed
Article
Google Scholar
Das P, et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer. 2007;109(9):1750–5.
CAS
PubMed
Article
Google Scholar
Al-Sukhni E, et al. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2016;23(4):1177–86.
PubMed
Article
Google Scholar
Armstrong D, et al. Predictors of pathologic complete response after neoadjuvant treatment for rectal cancer: a multicenter study. Clin Colorectal Cancer. 2015;14(4):291–5.
PubMed
Article
Google Scholar
Mace AG, et al. Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon rectum. 2013;56(11):1217–27.
PubMed
Article
Google Scholar
Karagkounis G, et al. Simvastatin enhances radiation sensitivity of colorectal cancer cells. Surg Endosc. 2017;32(3):1533–1539. https://doi.org/10.1007/s00464-017-5841-1
Shen L, et al. Baseline neutrophil-lymphocyte ratio (>/=2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Radiat Oncol. 2014;9:295.
PubMed
PubMed Central
Article
Google Scholar
Carruthers R, et al. Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Color Dis. 2012;14(10):e701–7.
CAS
Article
Google Scholar
Krauthamer M, et al. A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncology. 2013;85(1):27–32.
CAS
PubMed
Article
Google Scholar
•• Dossa F, et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(7):501–13. A significant study that provides a good overview on watch-and-wait and its outcomes.
PubMed
Article
Google Scholar
•• Kong JC, et al. Outcome and salvage surgery following “watch and wait” for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum. 2017;60(3):335–45. A good quality systematic review on the oncological outcomes expected with watch-and-wait.
PubMed
Google Scholar
• van der Valk M. International Watch Wait Database Consortium. The International Watch & Wait database (IWWD) for rectal cancer: an update. J Clin Oncol. 2017;35(4_suppl):521–1. An important report on the outcomes derived from the International W&W database.